bioRxiv Science⌕ Search

Biology subjects

Van Cura, D.

Publications and source records attributed to Van Cura, D..

3 recordsLinked to original sources

Chemical capture of diazo metabolites reveals biosynthetic hydrazone oxidation

Chemically reactive microbial natural products have enabled therapeutic development1,2 via their well-established bioactivities including anticancer,3 antibiotic,4,5 and antioxidant6 activities. However, discovery of reactive metabolites is particularly challenging because they may not tolerate traditional bioactivity-guided isolation workflows.7 Diazo-containing natural products are a subset of highly reactive microbial metabolites that display potent bioactivity8-11 and enable powerful (bio)synthetic transformations;12,13 however, instability of the diazo group to light,14,15 heat,16,17 mild acid,18 and mechanical shock19 has precluded their efficient discovery and application. Here, we develop a reactivity-based screening approach to capture diazo-containing metabolites and facilitate their discovery by mass spectrometry. This workflow revealed two novel diazo-containing natural products, 4-diazo-3-oxo-butanoic acid and diazoacetone, from the human lung pathogen Nocardia ninae. Biosynthetic investigations revealed a distinct enzymatic logic for diazo formation involving hydrazone oxidation catalyzed by the metalloenzyme Dob3, and biochemical characterization of Dob3 suggests promising future applications in biocatalysis. Overall, our work highlights the power of reactivity-guided strategies for identifying reactive metabolites and facilitating the discovery of unique enzymatic transformations.

biochemistry↗

The differential effect of glutamine supplementation on the orthotopic and subcutaneous growth of two syngeneic murine models of glioma

Glutamine serves as a major fuel source for tumor cell proliferation while simultaneously playing an essential role in maintaining gastrointestinal health and immune function. Controversy exists regarding glutamine supplementation for cancer patients undergoing chemotherapy and radiation, with concerns that it may stimulate cancer growth. The present study is the first to examine the effects of dietary glutamine supplementation (0.4g/kg/day) on the growth of malignant gliomas, which utilize large amounts of glutamine to satisfy metabolic demands. Brain bioluminescence and subcutaneous tumor volumes were used to assess the influence of glutamine supplementation on the growth of the syngeneic VM-M3 and CT-2A preclinical models of glioma. Glutamine supplementation had no significant effect on the orthotopic growth of the VM-M3 or the CT-2A gliomas when compared to non-supplemented controls. However, glutamine supplementation significantly increased tumor volume by 28% in the VM-M3 and by 166% in the CT-2A tumors when grown subcutaneously outside the central nervous system (CNS) relative to controls. Additionally, glutamine supplementation increased serum glutamine despite a localized decrease in intratumoral glutamine concentrations. Caution is warranted when considering glutamine supplementation in patients with glutamine-dependent malignancies. Further studies are needed to better understand the potential risks and benefits of glutamine supplementation in cancer therapy.

cancer biology↗

PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation

Preferentially Expressed Antigen in Melanoma (PRAME) and Ten-Eleven Translocation (TET) dioxygenase-mediated 5-hydroxymethylcytosine (5hmC) are emerging melanoma biomarkers. We observed an inverse correlation between PRAME expression and 5hmC levels in benign nevi, melanoma in situ, primary invasive melanoma, and metastatic melanomas via immunohistochemistry and multiplex immunofluorescence: nevi exhibited high 5hmC and low PRAME, whereas melanomas showed the opposite pattern. Single-cell multiplex imaging of melanoma precursors revealed that diminished 5hmC coincides with PRAME upregulation in premalignant cells. Analysis of TCGA and GTEx databases confirmed a negative relationship between TET2 and PRAME mRNA expression in melanoma. Additionally, 5hmC levels were reduced at the PRAME 5 promoter in melanoma compared to nevi, suggesting a role for 5hmC in PRAME transcription. Restoring 5hmC levels via TET2 overexpression notably reduced PRAME expression in melanoma cell lines. These findings establish a function of TET2-mediated DNA hydroxymethylation in regulating PRAME expression and demonstrate epigenetic reprogramming as pivotal in melanoma tumorigenesis. TeaserMelanoma biomarker PRAME expression is negatively regulated epigenetically by TET2-mediated DNA hydroxymethylation

cancer biology↗